Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE: Gefapixant Treatment Satisfaction in Refractory or Unexplained Chronic Cough
jRCTs041240123Recruiting
- Sponsor
- MSD
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of gefapixant in refractory chronic cough (RCC) and chronic idiopathic cough (CIC), sponsored by MSD. Primary endpoint: Treatment satisfaction determinants. Started Dec 2024; status: recruiting.
02
Drugs
gefapixant
03
Conditions
refractory chronic cough (RCC)chronic idiopathic cough (CIC)
Beyond the preview
Go deeper on jRCTs041240123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041240123.